Madduri, D.
Parekh, S.
Campbell, T. B.
Neumann, F.
Petrocca, F.
Jagannath, S.
Article History
Received: 26 October 2020
Accepted: 23 November 2020
First Online: 19 February 2021
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation guidelines for Good Clinical Practice and the protocol was approved by local or independent institutional review boards at each study center. All patients provided informed consent for participation in this clinical study.
: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent form is available for review by the Editor-in-Chief of this journal.
: D.M.: Advisory board and consulting fees from Janssen, Celgene, Bristol Myers Squibb, Takeda, Legend, Sanofi Genzyme, GlaxoSmithKline, Kinevant, and Foundation Medicine. S.P.: Consulting fees from Foundation Medicine, research funding from Celgene and Karyopharm. Supported by 1R01CA244899-01A1. T.C.: Employment and ownership of Bristol-Myers Squibb, F.P.: employment and ownership interest of bluebird bio, F.N.: prior employment and ownership interest of bluebird bio. S.J.: Advisory board and consulting fees from Celgene, Bristol‐Myers Squibb, Janssen Pharmaceuticals, and Merck.